Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcasertib in advanced hepatobiliary cancer
NCT02232633Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Feb 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amcasertib in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), sponsored by Sumitomo Pharma America. Started Feb 2015; status: completed.
02
Drugs
amcasertib
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02232633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232633.